Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.

Cardiovascular Drugs and Therapy
Waleed AlHabeebAhmed Adel Ibrahim Abdelsalam

Abstract

Bisoprolol and nebivolol are highly selective β1-adrenoceptor antagonists, with clinical indications in many countries within the management of heart failure with reduced left ventricular ejection fraction (HFrEF), ischaemic heart disease (IHD), and hypertension. Nebivolol has additional vasodilator actions, related to enhanced release of NO in the vascular wall. In principle, this additional mechanism compared with bisoprolol might lead to more potent vasodilatation, which in turn might influence the effectiveness of nebivolol in the management of HFrEF, IHD and hypertension. In this article, we review the therapeutic properties of bisoprolol and nebivolol, as representatives of "second generation" and "third generation" β-blockers, respectively. Although head-to-head trials are largely lacking, there is no clear indication from published studies of an additional effect of nebivolol on clinical outcomes in patients with HFrEF or the magnitude of reductions of BP in patients with hypertension.

References

Jun 19, 1976·British Medical Journal·A J MarshallD W Barritt
Jan 1, 1992·Journal of Sex & Marital Therapy·C P BroekmanA K Slob
Jan 1, 1990·European Journal of Clinical Pharmacology·M S DixonD J Sheridan
Nov 1, 1986·Journal of Clinical Pharmacology·G LeopoldK U Bühring
Jul 1, 1988·British Journal of Clinical Pharmacology·R LewisD G McDevitt
Dec 1, 1987·European Heart Journal·O De DivitiisR Gradnik
Jan 1, 1986·Clinical and Experimental Pharmacology & Physiology·J F Marwood, G S Stokes
Mar 1, 1994·International Journal of Cardiology·G RufH Roskamm
Jan 1, 1997·European Journal of Clinical Pharmacology·G CheymolJ M Poirier
Feb 19, 1998·Journal of Human Hypertension·L Van NuetenJ I Robertson
Mar 21, 1998·Journal of Human Hypertension·L Van NuetenJ I Robertson
Jun 25, 1999·BMJ : British Medical Journal·N FreemantleJ Harrison
Oct 12, 2000·Journal of Cardiovascular Pharmacology·P SchnabelM Böhm
Jan 29, 2002·Journal of Cardiovascular Pharmacology·J M Ritter
May 22, 2002·Circulation·Peter AndrekaNanette H Bishopric
Jun 11, 2003·Journal of Clinical Pharmacy and Therapeutics·S L NuttallM J Kendall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Cardiology in Review
Sachin S Sule, William Frishman
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Allison S DeryJessica A Starr
Cardiologia : bollettino della Società italiana di cardiologia
E Agabiti-RoseiC Monteduro
© 2021 Meta ULC. All rights reserved